GABRB2 and neoplasm: Increased expression of GABRB2 was correlated with several positive indicators of patient prognosis, including a lack of new neoplasm events following initial therapy (no new neoplasm: n = 33, avg ± SEM = 4.7 ± 0.42 log2 RSEM, new neoplasm: n = 35, avg ± SEM = 3.3 ± 0.4 log2 RSEM; unpaired t-test, p = 0.02).